Roohi Ismail-Khan - Moffitt Cancer Center

基本信息

浏览量：19

职业迁徙

个人简介

My current research interests are in cardio-oncology and women's cancers. My overall goal of clinical research is to minimize long term toxicity in patients who undergo chemotherapy and targeted therapy.

研究兴趣

论文共 89 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), As Monotherapy and in Combination with Abemaciclib, in Endometrioid Endometrial Cancer (EEC): Results from the EMBER Phase 1a/1b Study

Kan Yonemori,Kalyan Banda,Valentina Boni,Joohyuk Sohn,Tarek Meniawy,Janine Margaret Lombard,Peter A. Kaufman, Debra L. Richardson, Laura Bender Somme,Koji Matsumoto,Karthik Giridhar,Jose Angel Garcia Saenz,Hans Prenen,Bernard Doger de Speville Uribe,Don S. Dizon,Javier Garcia-Corbacho, Yujia Li,Bastien Nguyen,Roohi Ismail-Khan,Patrick Neven

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Abstract 6427: Phase II Study of Trametinib Alone and in Combination with Uprosertib in Patients with Metastatic Triple Negative Breast Cancer Previously Treated with Chemotherapy: OSU 13317

Vishnu Prasath,Hinda Boutrid,Ewa Mrozek,Maryam Lustberg, Robert Weslowski,Rachel Layman,Mahmoud Abdel-Rasoul,Cynthia Timmers,Erin MacRae,G. Thomas Budd,Lyndsay Harris,Claudine Isaacs,Roohi Ismail-Khan,Elizabeth Claire Dees,Andrew S. Poklepovic, Helen X. Chen,Miguel Villalona-Calero,William Carson, Gary L. Johnson,Daniel G. Stover,Bhuvaneswari Ramaswamy

Cancer Researchno. 6_Supplement (2024): 6427-6427

引用0浏览0引用

Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination with Human Epidermal Growth Factor Receptor 2 (HER2) Directed Therapy, with or Without Abemaciclib, in Estrogen Receptor (ER) Positive, HER2 Positive Advanced Breast Cancer (abc): EMBER Phase 1a/1b Study

Manali A. Bhave,Komal L. Jhaveri,Peter A. Kaufman,Philippe Georges Aftimos,Janine Margaret Lombard,Kostandinos Sideras,Seock-Ah Im,Cynthia X. Ma,Kuo-Ting Lee,Sung-Bae Kim, Yujia Li,Eunice Yuen,Shawn T. Estrem,Bastien Nguyen, Francesca Bacchion,Roohi Ismail-Khan,Muralidhar Beeram,Joohyuk Sohn

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, As Monotherapy and in Combination with Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.JCO2302733-JCO2302733, (2024)

引用0浏览0WOS引用

Abstract OT1-01-02: EMBER-4: A Phase 3 Adjuvant Trial of Imlunestrant Vs Standard Endocrine Therapy (ET) in Patients with ER+, HER2- Early Breast Cancer (EBC) with an Increased Risk of Recurrence Who Have Previously Received 2 to 5 Years of Adjuvant ET

Komal Jhaveri,Joyce O’Shaughnessy,Fabrice Andre,Matthew P. Goetz,Nadia Harbeck,Miguel Martín,Francois-Clement Bidard,Zachary M. Thomas,Suzanne Young,Roohi Ismail-Khan,Lillian M. Smyth,Michael Gnant

Cancer Researchno. 5_Supplement (2023): OT1-01

引用0浏览0引用

EMBER-4: a Phase 3 Adjuvant Trial of Imlunestrant Vs Standard Endocrine Therapy in Patients with ER+, HER2− Early Breast Cancer with an Increased Risk of Recurrence Who Have Previously Received 2 to 5 Years of Adjuvant ET

Komal Jhaveri,Joyce O'Shaughnessy,Fabrice Andre,Matthew P. Goetz,Nadia Harbeck,Miguel Martin,Francois-Clement Bidard,Zachary M. Thomas,Suzanne Young,Roohi Ismail-Khan,Lillian M. Smyth,Michael Gnant

CANCER RESEARCHno. 5 (2023)

引用0浏览0引用

COVID-19 Severity and Cardiovascular Outcomes in SARS-CoV-2-infected Patients with Cancer and Cardiovascular Disease

Melissa Y. Y. Moey,Cassandra Hennessy,Benjamin French,Jeremy L. Warner,Matthew D. Tucker,Daniel J. Hausrath,Dimpy P. Shah,Jeanne M. DeCara,Ziad Bakouny,Chris Labaki,Toni K. Choueiri,Susan Dent,Nausheen Akhter,Roohi Ismail-Khan,Lisa Tachiki,David Slosky,Tamar S. Polonsky,Joy A. Awosika, Audrey Crago,Trisha Wise-Draper,Nino Balanchivadze,Clara Hwang,Leslie A. Fecher,Cyndi Gonzalez Gomez,Brandon Hayes-Lattin,Michael J. Glover,Sumit A. Shah,Dharmesh Gopalakrishnan,Elizabeth A. Griffiths,Daniel H. Kwon,Vadim S. Koshkin,Sana Mahmood,Babar Bashir,Taylor Nonato,Pedram Razavi,Rana R. McKay,Gayathri Nagaraj, Eric Oligino,Matthew Puc, Polina Tregubenko,Elizabeth M. Wulff-Burchfield,Zhuoer Xie,Thorvardur R. Halfdanarson,Dimitrios Farmakiotis,Elizabeth J. Klein,Elizabeth V. Robilotti,Gregory J. Riely, Jean-Bernard Durand,Salim S. Hayek,Lavanya Kondapalli,Stephanie Berg,Timothy E. O'Connor,Mehmet A. Bilen,Cecilia Castellano,Melissa K. Accordino,Blau Sibel,Lisa B. Weissmann,Chinmay Jani,Daniel B. Flora,Lawrence Rudski,Miriam Santos Dutra,Bouganim Nathaniel,Erika Ruiz-Garcia,Diana Vilar-Compte,Shilpa Gupta,Alicia Morgans,Anju Nohria

Translational oncology (2023): 101709-101709

引用1浏览0WOS引用

Abstract P6-10-06: A Preoperative Window-of-opportunity Study of Imlunestrant in Estrogen Receptor-Positive, HER2-negative Early Breast Cancer: Results from the EMBER-2 Study

Patrick Neven, Nicole Stahl,Maria Vidal,Miguel Martín, Nadia Harbeck,Peter A. Kaufman,Francois-Clement Bidard, Peter A. Fasching,Philippe Aftimos,Erika Hamilton,Stacey Carter,Peter Schmid,Duncan Wheatley,Manali Bhave,Kelly K. Hunt,Swati A. Kulkarni,Roohi Ismail-Khan,Claudia Karacsonyi,Shawn T. Estrem,Umut Ozbek,Bastien Nguyen,Eva Ciruelos

Cancer researchno. 5_Supplement (2023): P6-06

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn